Pathogenetic basis of myocardial dysfunction and amenability to reversal

Cardiology Clinics

Volumn 21, Issue 1, 2003, Pages 83-91

  Garg, Shaila ^a   Narula, Jagat ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); MATRIX METALLOPROTEINASE;

APOPTOSIS; CALCIUM HOMEOSTASIS; CELL DEATH; CONGESTIVE HEART FAILURE; EXTRACELLULAR MATRIX; HEART ASSIST DEVICE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0038247935     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(02)00134-0     Document Type: Review

References (93)

1. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1677-86.
2. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-21.
3. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med 1984;311:850-1.
4. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-95.
5. Bozkurt B, Kribbs S, Clubb Jr FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodelling in rats. Circulation 1998;97:1382-91.
6. Mann DL, Kent RL, Parsons B, Cooper GIV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
7. Kapadia S, Dibbs Z, Kurrelmeyer K, et al. The role of cytokines in the failing human heart. Cardiol Clin 1998;16:645-56.
8. Torre-Amione G, Kapiada S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular function: a report from the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1997;27:1201-6.
9. Birks E, Latif N, Owen V, Bowles C, et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001;104(Suppl I1):233-41.
10. Ing DJ, Zang J, Dzau VJ, et al. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 1999;84:21-33.
11. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65.
12. Schulz R, Panas DL, Catena R, et al. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumor necrosis factor-alpha. Br J Pharmacol 1995;114:27-34.
13. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995;91:2504-7.
14. Douglas PS, Morrow R, Ioli A, Reicheck N. Left ventricular shape, afterload, and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989;13:311-5.
15. Vasan RS, Larson MG, Benjamin EJ, et al. Left ventricular dilation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997;336:1350-5.
16. Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am J Cardiol 1960;69:370-82.
17. Hirota Y, Saito T, Kita Y, et al. The natural history of dilated cardiomyopathy and pathophysiology of congestive heart failure. J Cardiogr 1986;69(Suppl):67-76.
18. Pouleur H, Rousseau MF, Van Eyll C, et al. Cardiac mechanics during development of heart failure. SOLVD Investigators Circulation 1993;87: IV14-20.
19. Ross Jr J. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. J Am Coll Cardiol 1985;5:811-26.
20. Ross Jr J. Mechanisms of cardiac contraction. What roles for preload, afterload and inotropic state in heart failure? Eur Heart J 1983;4(Suppl A):19-28.
21. Kapadia S, Oral H, Lee J, et al. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997;81:187-95.
22. Saoshima JI, Xu Y, Slayter HS, et al. Autocrine release of aniotensin II mediated strech-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-84.
23. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998;352(Suppl 1): S134-8.
24. Le Grice IJ, Takayama Y, Holmes JW, et al. Impaired subendocardial function in tachycardia-induced heart failure. Am J Physiol 1995;268: H1788-94.
25. Shannon RP, Komamura K, Shen YT, et al. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol 1993;265:H801-9.
26. Vatner SF. Reduced subendocardial myocardial perfusion as one mechanism of congestive heart failure. Am J Cardiol 1988;62:94E-8E.
27. Gerdes AM, Kellerman SE, Malec KB, Schocken DD. Transverse shape characteristics of cardiac myocytes from rats and humans. Cardioscience 1994;5:31-6.
28. Gerdes AM, Moore JA, Kellerman SE, et al. Similar change in cardiac myocyte shape in patients with ischemic and dilated cardiomyopathy [abstract]. Circulation 1992;86(Suppl I):I-425.
29. Goldstein S, Ali AS, Sabbah H. Ventricular remodeling mechanisms and prevention. Cardiol Clin 1998;16:645-56.
30. Kurrelmeyer K, Kalra D, Bozkurt B, et al. Cardiac remodeling as a consequence and cause of progressive heart failure. Clin Cardiol 1998;21(suppl 1):14-9.
31. Lowes BD, Minobe W, Abraham WT, et al. Changes in expression in the intact human heart. Downregulation of a-myosin heavy chain in hypertrophied failing ventricular myocardium. J Clin Invest 1997;100:2315-24.
32. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85:1046-55.
33. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and B-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
34. Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61:70-6.
35. Schaper J, Froede R, Hein ST, et al. Impairment of myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 1991;83:504-14.
36. Heling A, Zimmerman R, Kostin S, et al. Increased expression of cytoskeletal, linkage and extracellular proteins in failing human myocardium. Circ Res 2000;86:846-53.
37. Davies CH, Davia K, Bennett JG, et al. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995;92:2540-9.
38. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96:2953-8.
39. Kajstura J, Zhang X, Liu Y. The cellular basis of pacing induced dilated cardiomyopathy: myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995;92:2306-17.
40. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89:151-63.
41. Beltrami CA, Finato N, Rocco M, et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995;27:291-305.
42. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9.
43. Leri A, Claudio PP, Li Q, et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 1998;101:1326.
44. Wang Y, Su B, Sah VP, et al. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 1998;273:5423-6.
45. Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 1999;10:629.
46. Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure: release of cytochrome C from mitcochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 1999;96:8144-9.
47. Narula J, Arbustini E, Chandrashekhar Y, et al. Apoptosis and the systolic dysfunction in congestive heart failure: the story of apoptosis interruptus and zombie myocytes. Cardiol Clin 2001;19:113-21.
48. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end stage heart failure. Circulation 1998;97:1708-15.
49. Tyagi SC, Kumar S, Voelker DJ, et al. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 1996;63:185-98.
50. Weber KT. Extracellular matrix remodelling in heart failure. A role for de novo angiotensin II generation. Circulation 1997;96:4065-82.
51. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis functional significance and regulatory factors. Cardiovasc Res 1993;27:341-8.
52. Weber KT, Sun Y, Guarda E, Structural remodelling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869-77.
53. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728-34.
54. Mukherjee R, Hewett KW, Walker JD, et al. Changes in L-type calcium channel abundance and function during the transition to pacing-induced congestive heart failure. Cardiovasc Res 1998;37:432-44.
55. Mukherjee F, Spinale FG. L-type calcium abundance and function with cardiac hypertrophy and failure: a review. J Mol Cell Cardiol 1998;30:1899-916.
56. de la Bastie D, Levitsky D, Rappaport L, et al. Function of the sarcoplasmic reticulum and expression of its Ca(+)-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res 1990;66:554-64.
57. Lindner M, Erdmann E, Beuckelmann DJ, et al. Calcium content of the sarcoplasmic reticulum in isolated ventricular myocytes from patients with terminal heart failure. J Mol Cell Cardiol 1998;30:743-9.
58. Meyer M, Schillinger W, Peiske B, et al. Alterations of sarcoplasmic rcticulum proteins in failing dilated cardiomyopathy. Circulation 1995;92:778-84.
59. Schwinger RH, Bohm M, Schimdt U, et al. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 1995;92:3220-8.
60. Chein KR, Zhu H, Knowlton KU, et al. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993;55:77-95.
61. Swynghedauw B. Development and functional adaptation of contractile proteins in cardiac and skeletal muscle. Physiol Rev 1986;66:710-71.
62. Anderson PA, Malouf NN, Oakely AE, et al. Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 1991;69:1226-33.
63. Burch GE, DePasquale NP. On resting the human heart. Am J Med 1968;44:165-7.
64. Dippla K, Mattiello JA, Jeevanandam V, et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998;97:2316-22.
65. Frazier OH. First use of an untethered, vented electric left ventricular assist device for long-term support. Circulation 1994;89:2908-14.
66. Sheinen SA, Capek P, Radovancevic B, et al. The effect of prolonged left ventricular support on myocardial histopathology in patients with end-stage cardiomyopathy. ASAIO J 1992;38:M271-4.
67. Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the HeartMate 100 IP left ventricular assist device. Ann Thorac Surg 1992;53:1080-90.
68. Frazier OH, Benedict CR, Radovancevic B, et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg 1996;62:675-82.
69. Muller J, Wallukat G, Weng Y, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997;96:542-9.
70. Levin H, Oz M, Chen J, et al. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 1995;91:2717-20.
71. Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998;98:2383-9.
72. Mancini D, Goldsmith R, Levin H, et al. Comparison of exercise performance in patients with chronic severe heart failure versus left ventricular assist devices. Circulation 1998;98:1178-83.
73. Katz AM, Messineo F, Nash-Adler P. Effects of amphiphilic substances on sarcoplasmic reticulum function. In: Entman ML, Van Winkle WB, editors. Sarcoplasmic reticulum in muscle physiology, vol II. Boca Raton, FL: CRC Press; 1986. p. 123-39.
74. Barbone A, Holmes JW, Heerdt PM, et al. Comparison of right and left ventricular response to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation 2001;104:670-5.
75. Estrada-Quintero T, Uretsky BF, Murali S, et al. Amelioration of the heart failure state with left ventricular assist system support. J Am Coll Cardiol 1992;19(Suppl A):254A.
76. James KB, McCarthy PM, Thomas JD, et al. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 1995;92(Suppl II):191-5.
77. Levin H, Chen J, Oz M, et al. Potential for left ventricular assist devices as out-patient therapy while awaiting transplantation. Ann Thorac Surg 1994;58:1515-20.
78. Hetzer R, Muller J, Weng Y, et al. Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Ann Thorac Surg 1999;68:742-9.
79. Dipla K, Mattielo JA, Jeevanandam V, et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998;97:2316-22.
80. Torre-Amione G, Stetson S, Youker K, et al. Decreased expression of tumor necrosis factor-(alpha) in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 1999;100:1189-93.
81. Houel R, Vermes E, Tixier DB, et al. Myocardial recovery after mechanical support for acute myocarditis: is sustained recovery predictable? Ann Thorac Surg 1999;68:2177-80.
82. Duncan BW, Bohn DJ, Atz AM, et al. Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J Thorac Cardiovasc Surg 2001;122:440-8.
83. Burkhoff D, Holmes JW, Madigan J, et al. Left ventricular assist device-induced reverse ventricular remodeling. Prog Cardiovasc Dis 2000;43:19-26.
84. Zafeiridis A, Jeevanandam V, Houser SR, Marguilies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998;98:656-62.
85. McCarthy PM, Nakatani S, Vargo R, et al. Structural and left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg 1995;59:609-13.
86. Jacquet L, Zerbe T, Stein KL, et al. Evolution of human cardiac myocyte dimension during prolonged mechanical support. J Thorac Cardiovasc Surg 1991;101:256-9.
87. Nakatani S, McCarthy PM, Kottke-Marchant K, et al. Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. J Am Coll Cardiol 1996;27:894-901.
88. Belland SE, Jeevanandam V, Eisen HJ, et al. Reduced myocardial matrix metalloproteinase expression as a result of sustained mechanical support with left ventricular assist devices in patients with severe dilated cardiomyopathy [abstract]. J Heart Lung Transplant 1998;17:84.
89. Altemose GT, Gristus V, Jeevanandam V, et al. Altered myocardial phenotype after mechanical support in human beings with advanced cardiomyopathy. J Heart Lung Transplant 1997;16:765-73.
90. Heerdt PM, Schalme M, Jehle R, et al. Disease-specific remodeling of cardiac mitochondria after a left ventricular assist device. Ann Thorac Surg 2002;73:1216-21.
91. Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg 1999;68:734-41.
92. Bartling B, Milting H, Schulman H, et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation 1999;100:216-23.
93. Arbustini E, Norbini P, Narula J, et al. Apoptosis in heart failure: abrogation of cytochrome c release after ventricular unloading by LVAD [abstract]. Med Pathol 2001.